Lionbio

Lionbio is a company headquartered in the United States. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Lionbio develops a proprietary nanoparticle-based intranasal delivery platform for GLP-1 receptor agonists and other peptides, enabling nose-to-brain delivery that aims to reduce nausea and eliminate the need for injections. Their technology targets neurological indications and broader biologics with a non-invasive alternative to injectable therapies.